Michael Kaseta Sells 11,580 Shares of Liquidia Technologies, Inc. (NASDAQ:LQDA) Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 11,580 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $165,362.40. Following the transaction, the chief financial officer directly owned 406,412 shares of the company's stock, valued at $5,803,563.36. The trade was a 2.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Liquidia Technologies Price Performance

NASDAQ:LQDA traded up $0.41 during trading hours on Thursday, hitting $14.60. The company's stock had a trading volume of 1,563,026 shares, compared to its average volume of 1,308,757. The business's 50-day moving average is $14.89 and its two-hundred day moving average is $14.46. The company has a market capitalization of $1.25 billion, a PE ratio of -9.24 and a beta of -0.01. The company has a debt-to-equity ratio of 2.08, a quick ratio of 2.91 and a current ratio of 2.93. Liquidia Technologies, Inc. has a 52-week low of $8.26 and a 52-week high of $19.41.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to analysts' expectations of $3.23 million. Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. As a group, research analysts anticipate that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. HC Wainwright raised their price objective on shares of Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, May 28th. Oppenheimer set a $13.00 price objective on shares of Liquidia Technologies and gave the company an "underperform" rating in a report on Monday, May 19th. Raymond James Financial raised their price objective on shares of Liquidia Technologies from $27.00 to $29.00 and gave the company a "strong-buy" rating in a report on Friday, May 9th. BTIG Research restated a "buy" rating on shares of Liquidia Technologies in a report on Tuesday, May 27th. Finally, Wall Street Zen upgraded shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $26.89.

Institutional Trading of Liquidia Technologies

A number of institutional investors have recently added to or reduced their stakes in the stock. Corebridge Financial Inc. boosted its holdings in Liquidia Technologies by 2.3% during the fourth quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock worth $371,000 after buying an additional 694 shares in the last quarter. Ballentine Partners LLC boosted its holdings in Liquidia Technologies by 10.2% during the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company's stock worth $151,000 after buying an additional 1,119 shares in the last quarter. GAMMA Investing LLC raised its position in Liquidia Technologies by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares during the last quarter. Cetera Investment Advisers raised its position in Liquidia Technologies by 4.3% during the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after acquiring an additional 1,277 shares during the last quarter. Finally, Valmark Advisers Inc. raised its position in Liquidia Technologies by 7.4% during the first quarter. Valmark Advisers Inc. now owns 18,641 shares of the company's stock worth $275,000 after acquiring an additional 1,283 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).